Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CTOR

Citius Oncology Inc

Dec 11 • 04:00PM ET

1.08

Dollar change -0.02
Percentage change -1.82	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Scroll to Statements

Index	-	P/E	4.41	EPS (ttm)	0.24	Insider Own	94.81%	Shs Outstand	2.34M	Perf Week	-23.40%
Market Cap	77.00M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.35M	Perf Month	-20.00%
Income	1.93M	PEG	-	EPS next Q	-0.06	Inst Own	0.50%	Short Float	9.07%	Perf Quarter	-34.15%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	1.78%	Short Ratio	0.02	Perf Half Y	-90.32%
Book/sh	-0.46	P/B	-	EPS next Y	-	ROA	3.25%	Short Interest	0.03M	Perf Year	-89.67%
Cash/sh	0.00	P/C	-	EPS next 5Y	-	ROE	3.35%	52W Range	0.85 - 49.00	Perf YTD	-90.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	4.19%	52W High	-97.80%	Beta	-0.38
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	27.06%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	46.01	Volatility	23.09% 21.02%
Employees	-	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	3.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-44.59%	Payout	0.00%	Rel Volume	0.08	Prev Close	1.10
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	1.88M	Price	1.08
SMA20	-2.42%	SMA50	-5.16%	SMA200	-85.40%	Trades		Volume	148,124	Change	-1.82%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-27-24	Initiated	Maxim Group	Buy	$3

Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +6.30%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +8.38% -5.60%
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTOR

Citius Oncology Inc

Upgrade your FINVIZ experience